calliditas.se (CALT) Cash Funds per Share

Cash per share for the issuer reflects liquidity dynamics, where the current metric is 2.83. Calliditas Therapeutics (CALT) focuses on the therapy of Berger's disease, holding a leading position in the niche of rare nephrological pathologies. High R&D expenditures and patent protection create significant barriers to entry. The company is currently undergoing a phase of full integration into the structure of a large international holding.
Analytical breakdowns for Calliditas Therapeutics, Inc. (CALT)

Calliditas Therapeutics (CALT) is scaling its presence in the rare kidney disease market through the exclusivity of its drug Tarpeyo. Liquidity dynamics here depend directly on commercialization rates and operating expenses. This metric reflects the amount of available capital allocated per share, measuring the actual margin of safety. A high level protects against debt but may limit profitability. By analyzing the cash per share figure, an investor assesses the business's sustainability.